Table 2.
GI50 values of SIRT2 inhibitors across a variety of cell lines.
| Cell Line | Type | TM GI50 (μM) | AF8 GI50 (μM) | AF10 GI50 (μM) |
|---|---|---|---|---|
| MCF7 | Breast Cancer | 37.0 ± 4.5 | 42.6 ± 18.5 | 18.4 ± 6.0 |
| MDA-MB-468 | Breast Cancer | 15.7 ± 2.5 | 26.1 ± 6.4 | 13.4 ± 1.7 |
| MDA-MB-231 | Breast Cancer | 42.8 ± 6.5 | 27.2 ± 8.1 | 14.8 ± 4.1 |
| BxPC-3 | Pancreatic Cancer | 13.3 ± 3.5 | 72.4 ± 25.5 | 24.3 ± 5.0 |
| NCI-H23 | Lung Cancer | 16.4 ± 1.8 | 35.8 ± 14.2 | 15.6 ± 3.5 |
| A549 | Lung Cancer | 17.3 ± 6.0 | 20.8 ± 6.9 | 9.0 ± 3.9 |
| SW948 | Colorectal Cancer | 19.2 ± 3.5 | 30.0 ± 8.9 | 12.8 ± 3.5 |
| HCT116 | Colorectal Cancer | 131.6 ± 54.0 | 58.9 ± 26.5 | 54.4 ± 12.6 |
| CCD 841 CoN | Colon Cells | n.d.a | 136.8 ± 53.5 | 47.4 ± 7.0 |
| HME1 | Epithelial Cells | n.i.b | n.i. | n.i. |
a
nd: not determined.
b
ni: no inhibition.